New Drugs for an Elusive Cancer Target
Medical oncologist and lung cancer expert Roy S. Herbst, MD, PhD, discusses early data on drugs that target a mutated form of the KRAS protein.
Thanks to Lifesaving Cancer Research18,000,000cancer survivors in the United States are living with, through, and beyond their disease.
Your donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now